Health
QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer
CAMBRIDGE, Mass., November 10, 2025--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).
About this update from Ovid Therapeutics Inc.
[{"type":"image","alt":"QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer","displaySize":"","headline":null,"caption":"QurAlis Announces Appointment of Manoj Malhotra, M.D., as Chief Medical Officer","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":480,"url":"https://media.zenfs.com/en/business-wire.com/03cbb41194ce6610d197a20b09f775e3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/OirMSZZ5aNyVGMxW0a1uCw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTk2MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/03cbb41194ce6610d197a20b09f775e3","width":480,"height":480}},"lazy":false},{"type":"text","content":"Physician-scientist brings more than two decades of R&D leadership experience in neuroscience, rare disease, and pain modulation at organizations including AbbVie, Ovid Therapeutics, Eisai Pharmaceuticals, and Takeda","length":220,"tagName":"p","attribs":{}},{"type":"text","content":"CAMBRIDGE, Mass., November 10, 2025--(BUSINESS WIRE)--QurAlis Corporation, a clinical-stage biotechnology company driving scientific breakthroughs into powerful precision medicines that have the potential to alter the trajectory of neurodegenerative and neurological diseases, today announced that it has appointed Manoj Malhotra, M.D., as chief medical officer (CMO).","length":368,"tagName":"p"},{"type":"text","content":""Manoj is a recognized leader in neuroscience drug development, particularly in neurodegenerative diseases and epilepsy, with a proven record across the full spectrum of clinical development from early discovery through late-stage clinical development and regulatory approval," said Kasper Roet, Ph.D., chief executive officer and co-founder of QurAlis. "His extensive experience combined with a deep commitment to patients will be a great addition to QurAlis as we continue to advance our mission of making a real difference in the lives of people living with devastating intractable diseases like ALS for which there remains significant unmet medical need."","length":679,"tagName":"p"},{"type":"text","content":""QurAlis is at the forefront of ushering in a step-change in how we treat neurodegenerative and neurological diseases by pioneering the development of precision medicines based on genetic target breakthroughs," said Dr. Malhotra. "I am impress...